Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116870 · ClinicalTrials.gov registry record · Phase 2
MARS - Monitored Atherosclerosis Regression Study
A Phase 2 study of Coronary Artery Disease and Atherosclerosis, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 1
- Study location
NCT00116870: Completed Phase 2 study of Coronary Artery Disease and Atherosclerosis, sponsored by Merck Sharp & Dohme.
NCT00116870 is a Phase 2 study of Coronary Artery Disease and Atherosclerosis that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 270 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116870, a Phase 2 study of Coronary Artery Disease and Atherosclerosis, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.
Conditions Studied
Interventions
- DRUG lovastatin
Study Locations (1)
California
- Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 1985-06 |
| Est. Completion | 1992-02 |
| Phase | Phase 2 |
What the finished NCT00116870 record still lists
NCT00116870 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which lovastatin is the first listed.
NCT00116870 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00116870 about?
NCT00116870 is a clinical study titled "MARS - Monitored Atherosclerosis Regression Study". The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.
What is the current status of trial NCT00116870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 1985-06. Estimated completion is 1992-02.
What conditions does trial NCT00116870 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Atherosclerosis.
What interventions are being tested in trial NCT00116870?
The interventions under investigation include: lovastatin (DRUG).
Who is sponsoring clinical trial NCT00116870?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00116870 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00116870's enrollment target sits among peer trials
270 109th of 219 higher than 111 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
RECRUITING · Phase 2
-
Prevent Cardiac Surgery Associated AKI Trial
RECRUITING · Phase 2
-
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
COMPLETED · Phase 2
-
High Ticagrelor Loading Dose in STEMI
COMPLETED · Phase 2
-
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia